POMPANO BEACH, FL- January 8, 2012 – Inovio Pharmaceuticals Inc (AMEX: INO) surged up 4.85% and closed at $0.65 on a traded volume of 1.67 million shares. The PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies. Researchers will test whether a novel vaccine approach that combines genetically engineered DNA with an innovative vaccine delivery technology called electroporation could induce an immune response in humans that protects against malaria parasite infection.
Will INO Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here http://csrnewsdaily.com/c1/?company=INO
Rentech Inc (AMEX: RTK) is currently trading at $2.79 on a traded volume of 1.36 million shares. The 52-week range for the stock is $1.44 and $3.05. The Company has Price/Sales ratio of 2.64 and Price/Book ratio of 2.91. The 50-Day Moving Average and 200-Day Moving Average prices is $2.76 and $2.43 respectively. The Company owns and operates a nitrogen fertilizer plant in East Dubuque, Illinois, that manufactures and sells natural gas-based nitrogen fertilizer products within the corn-belt region in the United States.
How Should Investors Trade RTK After The Recent Momentum, Find Out Here http://csrnewsdaily.com/c1/?company=RTK
Vringo Inc (AMEX: VRNG) slipped 9.23% to $3.30 on a traded volume of 1.47 million shares. In the last one year, the stock is up over 250%. The 52-week range for the stock is $0.68 and $5.73.
Get Free Special Trend Analysis On VRNG Here http://csrnewsdaily.com/c1/?company=VRNG
Brigus Gold Corp (USA) (AMEX: BRD) soared 2.02% to $0.954 on a traded volume of 1.04 million shares. The Company announced that the production guidance for fiscal 2013 is 90,000 to 100,000 ounces and cash costs are expected to stabilize in the range of $700 - $750 per ounce.
Get Free Special Trend Analysis On BRD Here http://csrnewsdaily.com/c1/?company=BRD
Hemispherx BioPharma Inc (AMEX: HEB) decreased 1.29% to $0.276. The Rosen Law Firm reminds investors of the important February 22, 2013 lead plaintiff deadline in the class action filed on behalf of investors who purchased the securities of Hemispherx Biopharma Inc from March 19, 2012 through December 17, 2012. Hemispherx Biopharma is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.
Get Free Special Trend Analysis On HEB Here http://csrnewsdaily.com/c1/?company=HEB
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.